FDA hits Glenmark with warning letter over GMP failings 22-Oct-2019 By Nick Taylor The US FDA hits Glenmark’s manufacturing plant with a warning letter over quality problems first identified in 2010.
NEWS IN BRIEF Glenmark opts for Horizon’s gene edited cell lines 01-Oct-2019 By Ben Hargreaves Glenmark signs a full commercial license to utilize Horizon’s gene edited CHO cell lines to be added to the former’s biomanufacturing process.
US generics industry faces antitrust legal backlash over pricing 13-May-2019 By Ben Hargreaves Teva is at the centre of the allegations made by 44 US states, which suggests a number of companies collaborated to raise prices by as much as 2,000%.